Dr. Martens (LON:DOCS) Stock Price Down 11.6% – What’s Next?

Dr. Martens plc (LON:DOCS)’s share price fell 11.6% on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. 9,032,986 shares changed hands during mid-day trading, an increase of 342% from the average session volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Dr. Martens News Roundup

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating on DOCS, which supports investor confidence in the brand and long-term growth potential. Broker Rating
• Negative Sentiment: Dr. Martens projected flat revenue for 2026 while saying it will scale back discounts — a move that should help margins but signals limited top-line growth near term, which is weighing on the share price. Revenue Guidance Article

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Price Performance

The business has a fifty day moving average of GBX 76.53 and a 200 day moving average of GBX 83.47. The firm has a market cap of £646.63 million, a P/E ratio of 39.35, a PEG ratio of 6.40 and a beta of 0.11. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, sell-side analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Robert Hanson acquired 96,000 shares of Dr. Martens stock in a transaction on Friday, December 5th. The stock was purchased at an average cost of GBX 79 per share, with a total value of £75,840. Insiders have acquired 97,130 shares of company stock worth $7,673,816 over the last three months. Insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.